Compare ADMA Biologics Inc (ADMA) vs e l f Beauty Inc (ELF) Price & Performance

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.

Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.